MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

150.93 +1.24 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,284,287
Open 150.05
Bid (Size) 149.00 (200)
Ask (Size) 152.18 (100)
Prev. Close 149.69
Today's Range 148.02 - 151.00
52wk Range 108.46 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK ↗
iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗
XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification. 
Via The Motley Fool
Topics ETFs

Performance

YTD
+24.1%
+24.1%
1 Month
+1.4%
+1.4%
3 Month
+19.5%
+19.5%
6 Month
+10.7%
+10.7%
1 Year
+34.6%
+34.6%

More News

Read More
News headline image
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗
Via The Motley Fool
Topics ETFs
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗
Via Chartmill
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗
Via The Motley Fool
Topics ETFs
News headline image
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
Via StockStory
News headline image
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig ↗
Via MarketBeat
News headline image
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances ↗
Via MarketBeat
Topics Intellectual Property
News headline image
PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors? ↗
Via The Motley Fool
Topics ETFs
News headline image
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
From Gilead Sciences, Inc.
Via Business Wire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth ↗
Via MarketBeat
News headline image
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode ↗
Via MarketBeat
News headline image
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
Via StockStory
Topics Stocks
News headline image
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? ↗
Via The Motley Fool
News headline image
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗
Via The Motley Fool
Topics ETFs
News headline image
FDA Approves Gilead's New Single Tablet HIV Regimen ↗
Via Benzinga
News headline image
3 Unpopular Stocks with Open Questions
Via StockStory
News headline image
Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗
Via The Motley Fool
Topics ETFs
News headline image
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
From Gilead Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 150.93
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 09/25/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 189.24B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 189B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story